La MG maternelle représente un risque pour l’enfant par le biais d’un transfert d’AC, d’un traitement immunosuppresseur

Verrouillé
Avatar du membre

Auteur du sujet
Pboulanger Prés.
Administrateur
Administrateur
Messages : 10762
Enregistré le : 02 févr. 2010 18:41
14
Localisation  : La Chapelle en Serval F-60520
Genre :
Zodiaque :
Âge : 67
    Windows 10 Firefox

La MG maternelle représente un risque pour l’enfant par le biais d’un transfert d’AC, d’un traitement immunosuppresseur

Message par Pboulanger Prés. »

:hi:

:arrow: Lu sur :https://www.ncbi.nlm.nih.gov/pubmed/30133097

[hr][/hr]

Traduction disponible directement en cliquant en bas à droite de ce message sur l'expression Traduire en

Image

[hr][/hr]

Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence.
Gilhus NE1,2, Hong Y1.
Eur J Neurol. 2018 Aug 22. doi: 10.1111/ene.13788. [Epub ahead of print]


Abstract



  • BACKGROUND:

    Females with myasthenia gravis (MG) worry about their disease having negative consequences for their children. Autoimmune disease mechanisms, treatment and heredity could all have an impact on the child.
  • METHODS:

    This is a subject review where Web of Science was searched for relevant key words and combinations. Controlled and prospective studies were included, and also results from selected and unselected patient cohorts, guidelines, consensus papers, and reviews.
  • RESULTS:

    Neonatal MG with temporary muscle weakness occurs in 10% of newborn babies where mother has MG, due to transplacental transfer of antibodies against acetylcholine receptor (AChR), muscle-specific kinase (MuSK) or lipoprotein receptor-related protein 4 (LRP4). Arthrogryposis and fetal AChR inactivation syndrome with contractures and permanent myopathy are rare events caused by mother's antibodies against fetal type AChR. The MG drugs pyridostigmine, prednisolone and azathioprine are regarded as safe during pregnancy and breastfeeding. Methotreaxate, mycophenolate mofetil and cyclophosphamide are teratogenic. Mother's MG implies at least a ten-fold increased risk for MG and other autoimmune disease in the child.
  • CONCLUSIONS:

    MG females should receive specific information about pregnancy and giving birth. First-line MG treatments should usually be continued during pregnancy. Intravenous immunoglobulin and plasma exchange represent safe treatments for exacerbations. Neonatal MG risk means that MG women should give birth at hospitals experienced in neonatal intensive care. Neonatal MG needs supportive care, rarely also acetylcholine esterase inhibition or intravenous immunoglobulin. Women with MG should be supported in their wish to have children. This article is protected by copyright. All rights reserved
.


[hr][/hr]

Sur demande de nos donateurs, nous pouvons faire l'acquisition d'un tiré-à-part de l'article intégral
coût : USD 41,50 $


[hr][/hr]
Message d' un membre de l'équipe technique
Pour les utilisateurs d'I-phone
ci-dessous le lien vers Google Trad

https://translate.google.fr/translate?h ... 2F30133097
Message d' un membre de l'équipe technique
Nous utilisons des services automatiques de traduction fournis
par Yandex ou Google.
Soyez vigilant sur le risque de contre-sens inhérent à ce genre d'outils.
Amicalement,
Image
Verrouillé

Retourner vers « 2018 »